Veracyte (VCYT) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Veracyte published the results on November 4, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Veracyte reports EPS two ways: GAAP, under the accounting rules every US filer follows, and non-GAAP, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Q3 2026 GAAP net income includes a $10.4 million income tax benefit. Veracyte's 10-Q attributes its 2026 tax benefit mainly to the release of a valuation allowance on federal and state deferred tax assets.
• Decipher Prostate and Afirma revenue are rounded figures from the release text; Veracyte does not print their year-ago dollar amounts, only growth of 12% and 19%.

Source: Veracyte Q3 2026 results release, November 4, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Veracyte splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Veracyte's Testing revenue revenue was $146 million in Q3 2026, up 15% from $128 million in Q3 2025, 96% of total revenue.
• Veracyte's Product revenue revenue was $4.6 million in Q3 2026, up 40% from $3.3 million in Q3 2025, 3% of total revenue.
• Veracyte's Biopharmaceutical and other revenue revenue was $0.7 million in Q3 2026, down 13% from $0.8 million in Q3 2025, under 1% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 2026 release, Veracyte said:

“Veracyte now expects 2026 total revenue guidance of $590 million to $593 million, representing 14% to 15% growth, compared to prior guidance of $590 million to $596 million.”

“This reflects testing revenue of $571 million to $573 million, representing 16% growth, compared to prior guidance of $576 million to $582 million, with minimal revenue contribution from recently launched tests.”

“Further, the company continues to expect adjusted EBITDA margin of greater than 26% for 2026.”

Source: Veracyte Q3 2026 release, Nov 4, 2026.

This is the company's own guidance as of Nov 4, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the VCYT forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP revenue and diluted EPS, each as first reported. Q4 2025 is from Veracyte's fourth-quarter release, which prints revenue to one decimal in millions.

We do not hold a confirmed date for Veracyte's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 4, 2026

Veracyte's Q3 2026 revenue was $151.8 million, up 15% from $131.9 million. Testing revenue was $146.4 million, up 15%. Product revenue rose 40% to $4.6 million on adoption of the Prosigna IVD after the phase III OPTIMA trial results, and biopharmaceutical and other revenue was $0.7 million. (Veracyte Q3 2026 release (8-K Exhibit 99.1), Nov 4, 2026)

Two tests make up most of Veracyte's testing revenue. Decipher Prostate grew 12% to $92.3 million on about 29,900 tests, and Afirma, a thyroid nodule test, grew 19% to $51.5 million on about 19,100 tests. Total testing volume rose 13% to 49,498 tests. Veracyte's CEO said Afirma outperformed while Decipher Prostate volume was below the company's expectations. (Veracyte Q3 2026 release (8-K Exhibit 99.1), Nov 4, 2026; Veracyte Form 10-K, 2025, Feb 26, 2026)

Veracyte's revenue depends heavily on a few payers. Medicare accounted for 33% of total revenue in the quarter and UnitedHealthcare for 13%, so the two together were 46%, against 47% a year earlier. (Veracyte Form 10-Q, Q3 2026, Nov 5, 2026)

Veracyte bought Convergent Genomics, maker of the UroAmp urine test for bladder cancer, for total consideration of $178.2 million, including $154.7 million in cash. Veracyte also secured Medicare reimbursement for its Prosigna Breast Risk of Recurrence test for eligible early-stage HR+ breast cancer patients. (Veracyte Form 10-Q, Q3 2026, Nov 5, 2026; Veracyte Q3 2026 release (8-K Exhibit 99.1), Nov 4, 2026)

Veracyte earned $0.38 per diluted share in Q3 2026, up from $0.24, on net income of $31.5 million. Income from operations fell to $16.6 million from $22.9 million, and the rise in net income came from other income of $4.6 million and a $10.4 million income tax benefit, an effective tax rate of negative 49.2%. (Veracyte Q3 2026 release (8-K Exhibit 99.1), Nov 4, 2026; Veracyte Form 10-Q, Q3 2026, Nov 5, 2026)

Veracyte's non-GAAP EPS of $0.51 was flat. It adds back stock-based compensation ($0.17 per share), intangible amortization ($0.04), acquisition-related expenses ($0.02) and other items ($0.04, mainly $3.2 million of legal proceedings expense), then removes $0.14 of tax adjustments, which strips out most of the quarter's tax benefit. (Veracyte Q3 2026 release (8-K Exhibit 99.1), Nov 4, 2026)

Veracyte's research and development expense rose 101% to $32.2 million. The 10-Q says $6.5 million of that came from software costs moved out of general and administrative. Diluted shares rose to 82,783,915 from 79,691,703, and the board authorized a share repurchase program of up to $100 million. (Veracyte Form 10-Q, Q3 2026, Nov 5, 2026; Veracyte Q3 2026 release (8-K Exhibit 99.1), Nov 4, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Veracyte gives a full-year outlook in its release. It now expects 2026 total revenue of $590 million to $593 million, 14% to 15% growth, against prior guidance of $590 million to $596 million. Testing revenue guidance was cut to $571 million to $573 million from $576 million to $582 million, and Veracyte still expects an adjusted EBITDA margin above 26%. (Veracyte Q3 2026 release (8-K Exhibit 99.1), Nov 4, 2026)

A consensus figure is the average of the models published by the analysts who cover Veracyte, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Veracyte's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning VCYT is on is VCYT a buy or a sell?, what analysts expect next is on the VCYT forecast, and what the company does is on the Veracyte (VCYT) stock page.

Every number on this page can be traced to a document Veracyte published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.